Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
Biologics
•
Pulmonology
•
Immunosuppression
How do you approach initiation/continuation of biologics if there is a suspicious pulmonary nodule that requires close interval imaging (i.e every 3 or 6 months)?
Related Questions
How do you approach endocarditis prophylaxis for patients with rheumatic diseases undergoing invasive dental surgery and no history of joint replacement?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?
Do you hold rituximab for cataract surgery?
What is your approach to RSV vaccination in immunocompromised patients?
How do you approach management of adult patients with CVID and sarcoid-like syndrome?
Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?
For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?
Do you consider IgM or IgA levels in addition to IgG levels when planning further doses of rituximab?